Dugard, Marit-NaomiSharp, Christopher A.Evans, Sally F.Williams, John H. H.Davie, Michael W. J.Marshall, Michael J.2009-05-112009-05-112005-06Clinica Chimica Acta, 356(1-2), (2005), pp. 154-163.0009-898110.1016/j.cccn.2005.01.020http://hdl.handle.net/10034/67764This article is not available through ChesterRep.Osteoclast differentiation and activity, and hence bone loss, depend on two opposing cytokines. Receptor activator of NF-κB ligand (RANKL) produced by osteoblasts and T-cells stimulates, while osteoprotegerin inhibits. Both of these cytokines are found in serum. Our aim was to develop a functional assay for any factors present in human serum that can affect osteoclast differentiation and to assess whether any such factors vary in diseases in which bone loss occurs.enosteoclastdifferentiationserumbone diseaseArticleClinica Chimica Acta